Inj. margetuximab-cmkb, 5 mg
Products billed under this code include Margenza.
Payment limit per 5 MG, by effective quarter, 4Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Margenza.
Payment limit per 5 MG, by effective quarter, 4Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Margenza | MacroGenics, Inc | 74527-0022-02 | 50 | $2,802.30 |
| Margenza | MacroGenics, Inc | 74527-0022-03 | 200 | $11,209.20 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $56.046 | −$0.396 | 5 MG | Inj. margetuximab-cmkb, 5 mg | v1, posted September 17, 2026 |
| 3Q26 | $56.442 | +$3.17 | 5 MG | Inj. margetuximab-cmkb, 5 mg | v1, posted September 15, 2026 |
| 2Q26 | $53.272 | −$0.477 | 5 MG | Inj. margetuximab-cmkb, 5 mg | v1, posted September 15, 2026 |
| 1Q26 | $53.749 | +$1.263 | 5 MG | Inj. margetuximab-cmkb, 5 mg | v1, posted September 15, 2026 |
| 4Q25 | $52.486 | +$2.036 | 5 MG | Inj. margetuximab-cmkb, 5 mg | v1, posted September 8, 2026 |
| 3Q25 | $50.45 | +$1.92 | 5 MG | Inj. margetuximab-cmkb, 5 mg | v1, posted March 10, 2026 |
| 2Q25 | $48.53 | −$0.87 | 5 MG | Inj. margetuximab-cmkb, 5 mg | v1, posted March 10, 2026 |
| 1Q25 | $49.40 | +$1.192 | 5 MG | Inj. margetuximab-cmkb, 5 mg | v1, posted December 19, 2025 |
| 4Q24 | $48.208 | +$0.068 | 5 MG | Inj. margetuximab-cmkb, 5 mg | v1, posted June 11, 2025 |
| 3Q24 | $48.14 | +$1.104 | 5 MG | Inj. margetuximab-cmkb, 5 mg | v1, posted June 11, 2025 |
| 2Q24 | $47.036 | −$0.015 | 5 MG | Inj. margetuximab-cmkb, 5 mg | v1, posted March 11, 2025 |
| 1Q24 | $47.051 | +$1.121 | 5 MG | Inj. margetuximab-cmkb, 5 mg | v1, posted December 19, 2024 |
| 4Q23 | $45.93 | +$0.049 | 5 MG | Inj. margetuximab-cmkb, 5 mg | v1, posted October 10, 2024 |
| 3Q23 | $45.881 | +$0.84 | 5 MG | Inj. margetuximab-cmkb, 5 mg | v1, posted June 5, 2024 |
| 2Q23 | $45.041 | +$0.053 | 5 MG | Inj. margetuximab-cmkb, 5 mg | v1, posted February 23, 2024 |
| 1Q23 | $44.988 | +$0.819 | 5 MG | Inj. margetuximab-cmkb, 5 mg | v1, posted December 6, 2023 |
| 4Q22 | $44.169 | +$0.137 | 5 MG | Inj. margetuximab-cmkb, 5 mg | v1, posted June 22, 2023 |
| 3Q22 | $44.032 | +$0.357 | 5 MG | Inj. margetuximab-cmkb, 5 mg | v1, posted June 9, 2023 |
| 2Q22 | $43.675 | −$0.082 | 5 MG | Inj. margetuximab-cmkb, 5 mg | v1, posted December 14, 2022 |
| 1Q22 | $43.757 | −$0.116 | 5 MG | Inj. margetuximab-cmkb, 5 mg | v1, posted June 8, 2022 |
| 4Q21 | $43.873 | – | 5 MG | Inj. margetuximab-cmkb, 5 mg | v1, posted June 2, 2022 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.